Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Start 7-day free trial → Log in

Sunitinib · Sutent

Small molecule · Inhibitor of platelet-derived growth factor receptor alpha (PDGFRA), platelet-derived growth factor receptor beta (PDGFRB) and vascular endothelial growth factor receptor 1 (FLT4) · developed by Pfizer Laboratories Div Pfizer

Approved FDA

4 Registered trials

What is Sunitinib?

Sunitinib is a small-molecule inhibitor of multiple receptor tyrosine kinases including PDGFR, VEGFR, KIT, FLT3, CSF-1R, and RET. It blocks angiogenesis and tumor cell proliferation.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as: Sutent
Drug type: Small molecule
Targets: platelet-derived growth factor receptor alpha (PDGFRA), platelet-derived growth factor receptor beta (PDGFRB), vascular endothelial growth factor receptor 1 (FLT4), vascular endothelial growth factor receptor 2 (KDR), KIT proto-oncogene receptor tyrosine kinase (KIT)
Mechanism: Inhibitor of platelet-derived growth factor receptor alpha (PDGFRA), platelet-derived growth factor receptor beta (PDGFRB) and vascular endothelial growth factor receptor 1 (FLT4)
Pathways: angiogenesis, cell proliferation
Therapy area: Oncology
Developer: Pfizer Laboratories Div Pfizer Inc
In trials of: BMY, COGT
FDA status: Approved as Sutent, NDA021938 · FDA label

✅ FDA-approved uses

Gastrointestinal stromal tumor (GIST) after disease progression on or intolerance to imatinib mesylate
Advanced renal cell carcinoma (RCC)
Adjuvant treatment of renal cell carcinoma (RCC) at high risk of recurrence following nephrectomy
Progressive, well-differentiated pancreatic neuroendocrine tumors (pNET)

From the indications section of the FDA label (version of Feb 20, 2026). Read the full label for the exact wording, limitations and safety information.

🧪 Clinical trials

Trial	Phase	Condition	Status	Sponsor
NCT05208047	Phase 3	Advanced Gastrointestinal Stromal Tumors	Recruiting	COGT
NCT06208748	Phase 2	Gastrointestinal Stromal Tumors	Active not recruiting	COGT
NCT03899155	Phase 2	Cancer	Recruiting	BMY
NCT02693535	Phase 2	Lymphoma, Non-Hodgkin	Recruiting	BMY

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Advanced Gastrointestinal Stromal TumorsAdvanced Solid TumorsCancerGastrointestinal Stromal TumorsGISTLymphoma, Non-HodgkinMetastatic CancerMultiple Myeloma

Other drugs acting on PDGFRA / PDGFRB / FLT4 / KDR / KIT

Midostaurin FDA approved Nintedanib FDA approved Pexidartinib FDA approved Regorafenib FDA approved 89Zr-DFOsq-olaratumab Phase 1 Barzolvolimab Phase 3 Bezuclastinib Phase 3 Briquilimab Phase 1/2 CDX 0158 Phase 1 Cediranib Phase 3 Olverembatinib Phase 3 Sitravatinib Phase 3

Sources

Updated Oct 3, 2026.

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z